Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24450216 | 0.84 | NAAA (0.41) | CYP4F2CYP4A11LMNA | |
| SCHEMBL24831388 | 0.83 | MAPK1 (0.38) | CYP1A2CTSK | |
| SCHEMBL27416269 | 0.82 | MMP8 (0.32) | CYP1A2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL15113292 | 0.81 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL23940761 | 0.79 | LMNA (0.32) | CYP1A2HSD17B10LMNA | |
| SCHEMBL24702528 | 0.79 | CYP1A2 (0.32) | CYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL13271929 | 0.76 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL22845072 | 0.75 | GAA (0.38) | — | |
| SCHEMBL18647824 | 0.75 | — | — | |
| SCHEMBL22609458 | 0.75 | LMNA (0.38) | CYP4F2CYP4A11HSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |